On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema. Read more.
FDA approves Lucentis to treat diabetic retinopathy
Most Recent Content
For Nurse Practitioners
Quiz: Migraines and Hormones
Women are 2 to 3 times more likely than men to have migraines. Decades ago, these were attributed to women’s inability to cope with...
